A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis



Status:Completed
Conditions:Neurology, Neurology, Multiple Sclerosis
Therapuetic Areas:Neurology, Other
Healthy:No
Age Range:18 - 60
Updated:5/19/2018
Start Date:October 18, 2016
End Date:April 20, 2018

Use our guide to learn which trials are right for you!

An Escalating Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis

This study seeks to evaluate the safety, tolerability, pharmacokinetics (PK) and
immunogenicity of ABT-555 in participants with relapsing forms of multiple sclerosis (RFMS).


Inclusion Criteria:

- Currently receiving one of the following MS medications for at least 3 months:
beta-interferon (any formulation including the pegylated form), glatiramer acetate
(Copaxone®, others), teriflunomide (Aubagio®), fingolimod (Gilenya®), or dimethyl
fumarate (Tecfidera®); OR

- Has not been treated with an MS immunotherapy for the past 6 months (12 months if they
previously received cyclophosphamide or alemtuzumab); OR

- Treatment naïve with established MS diagnosis per criteria by a neurologist.

- Diagnosis of relapsing-remitting MS (RRMS) or secondary progressive MS (SPMS)
according to revised McDonald criteria

- Baseline Expanded Disability Status Scale (EDSS) between 0 and 6.0, inclusive.

- Brain MRI scan at Screening that did not show evidence of overt vascular lesions,
masses, mass effect or other abnormalities other than those compatible with MS, which
would preclude the participant from undergoing a lumbar puncture/spinal tap for CSF
collection

Exclusion Criteria:

- Diagnosis of primary progressive MS.

- Anticipated maintenance immunomodulator change, either agent or dose

- An MS relapse that occurred within the 30 days prior to randomization AND/OR the
participant has not stabilized from a previous relapse prior to randomization

- Participants for whom MRI is contraindicated

- Participants who have claustrophobia that cannot be medically managed or are unable to
lie still for 1 hour or more for the imaging procedures

- Findings on brain MRI scan indicating any clinically significant brain abnormality
other than MS

- Contraindication for lumbar puncture
We found this trial at
8
sites
100 West Gore St # 202
Orlando, Florida 32806
(407) 426-9299
Compass Research LLC Compass Research is a clinical research company dedicated to testing new medications...
?
mi
from
Orlando, FL
Click here to add this to my saved trials
6355 Walker Lane
Alexandria, Virginia 22310
?
mi
from
Alexandria, VA
Click here to add this to my saved trials
Baltimore, Maryland 22125
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
2301 Erwin Rd
Durham, North Carolina 27710
919-684-8111
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
?
mi
from
Durham, NC
Click here to add this to my saved trials
Farmington Hills, Michigan 48334
?
mi
from
Farmington Hills, MI
Click here to add this to my saved trials
Houston, Texas 77074
?
mi
from
Houston, TX
Click here to add this to my saved trials
1321 Sunset Drive
Johnson City, Tennessee 37604
?
mi
from
Johnson City, TN
Click here to add this to my saved trials
Lenexa, Kansas 66214
?
mi
from
Lenexa, KS
Click here to add this to my saved trials